Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

被引：142

作者：

Mailänder, V ^{[1
]}

Scheibenbogen, C ^{[1
]}

Thiel, E ^{[1
]}

Letsch, A ^{[1
]}

Blau, IW ^{[1
]}

Keilholz, U ^{[1
]}

机构：

[1] Charite Univ Med Berlin, Med Klin 3, D-12200 Berlin, Germany

来源：

LEUKEMIA | 2004年 / 18卷 / 01期

关键词：

D O I：

10.1038/sj.leu.2403186

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：165 / 166

页数：2

共 10 条

[1] Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients [J].

Cilloni, D ;

Gottardi, E ;

De Micheli, D ;

Serra, A ;

Volpe, G ;

Messa, F ;

Rege-Cambrin, G ;

Guerrasio, A ;

Divona, M ;

Lo Coco, F ;

Saglio, G .

LEUKEMIA, 2002, 16 (10) :2115-2121

[2] Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells [J].

Inoue, K ;

Tamaki, H ;

Ogawa, H ;

Oka, Y ;

Soma, T ;

Tatekawa, T ;

Oji, Y ;

Tsuboi, A ;

Kim, EH ;

Kawakami, M ;

Akiyama, T ;

Kishimoto, T ;

Sugiyama, H .

BLOOD, 1998, 91 (08) :2969-2976

[3] Wilms' tumor gene expression in human CD34(+) hematopoietic progenitors during fetal development and early colonogenic growth [J].

Menssen, HD ;

Renkl, HJ ;

Entezami, M ;

Thiel, E .

BLOOD, 1997, 89 (09) :3486-3487

[4]

MENSSEN HD, 1995, LEUKEMIA, V9, P1060

[5] Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product [J].

Oka, Y ;

Elisseeva, OA ;

Tsuboi, A ;

Ogawa, H ;

Tamaki, H ;

Li, HF ;

Oji, Y ;

Kim, EH ;

Soma, T ;

Asada, M ;

Ueda, K ;

Maruya, E ;

Saji, H ;

Kishimoto, T ;

Udaka, K ;

Sugiyama, H .

IMMUNOGENETICS, 2000, 51 (02) :99-107

[6] Cancer immunotherapy targeting Wilms' tumor gene WT1 product [J].

Oka, Y ;

Udaka, K ;

Tsuboi, A ;

Elisseeva, OA ;

Ogawa, H ;

Aozasa, K ;

Kishimoto, T ;

Sugiyama, H .

JOURNAL OF IMMUNOLOGY, 2000, 164 (04) :1873-1880

[7] WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies [J].

Rosenfeld, C ;

Cheever, MA ;

Gaiger, A .

LEUKEMIA, 2003, 17 (07) :1301-1312

[8] CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia [J].

Scheibenbogen, C ;

Letsch, A ;

Thiel, E ;

Schmittel, A ;

Mailaender, V ;

Baerwolf, S ;

Nagorsen, D ;

Keilholz, U .

BLOOD, 2002, 100 (06) :2132-2137

[9] Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides [J].

Scheibenbogen, C ;

Schadendorf, D ;

Bechrakis, NE ;

Nagorsen, D ;

Hofmann, U ;

Servetopoulou, F ;

Letsch, A ;

Philipp, A ;

Foerster, MH ;

Schmittel, A ;

Thiel, E ;

Keilholz, U .

INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (02) :188-194

[10] Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias [J].

Siehl, JM ;

Thiel, E ;

Heufelder, K ;

Snarski, E ;

Schwartz, S ;

Mailänder, V ;

Keilholz, U .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (02) :235-242

← 1 →